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Hypomethylating agents (HMAs) are widely used in patients with higher-
risk myelodysplastic syndromes (MDS) not eligible for stem cell transplan-
tation; however, the response rate is <50%. Reliable predictors of response
are still missing, and it is a major challenge to develop new treatment
strategies. One current approach is the combination of azacytidine (AZA)
with checkpoint inhibitors; however, the potential benefit of targeting the
immunomodulator indoleamine-2,3-dioxygenase (IDO-1) has not yet been
evaluated. We observed moderate to strong IDO-1 expression in 37% of
patients with high-risk MDS. IDO-1 positivity was predictive of treatment
failure and shorter overall survival. Moreover, IDO-1 positivity correlated
inversely with the number of infiltrating CD8+ T cells, and IDO-1+
patients failed to show an increase in CD8+ T cells under AZA treatment.
In vitro experiments confirmed tryptophan catabolism and depletion of
CD8+ T cells in IDO-1+ MDS, suggesting that IDO-1 expression induces
an immunosuppressive microenvironment in MDS, thereby leading to
treatment failure under AZA treatment. In conclusion, IDO-1 is expressed
in more than one-third of patients with higher-risk MDS, and is predictive
of treatment failure and shorter overall survival. Therefore, IDO-1 is
emerging as a promising predictor and therapeutic target, especially for
combination therapies with HMAs or checkpoint inhibitors.
Keywords: myelodysplastic syndromes, immunmodulation, indoleamine-
2,3-dioxygenase, azacytidine, prognosis.
Myelodysplastic syndromes (MDS) are a group of clonal
haematopoietic stem cell disorders characterised by dysplasia,
bone marrow failure and an increased risk of developing sec-
ondary acute myeloid leukaemia (sAML). The prognosis of
higher-risk patients is generally poor, with a high rate of
early mortality, a low complete response (CR) and high
relapse rates even after intensive chemotherapy or allogeneic
haematopoietic stem cell transplantation (HSCT).1
Hypomethylating agents (HMAs), such as azacytidine
(AZA), have improved overall survival (OS) compared to
conventional care options, and are approved for patients
with higher-risk MDS not eligible for allogeneic HSCT.2–4
However, resistance to HMAs occurs in more than 50% of
patients. Furthermore, higher-risk MDS frequently progresses
to sAML even under ongoing therapy with AZA, and virtu-
ally all responders eventually relapse.5 While somatic muta-
tions in TP536–8 have been associated with poor OS in some
patient cohorts, the mechanisms of resistance to HMAs are
still not well understood. Therefore, it is essential to identify
reliable predictive markers and alternative treatment options.
research paper
ª 2020 The Authors. British Journal of Haematology published by British Society for Haematology
and John Wiley & Sons Ltd. British Journal of Haematology, 2020, 190, 361–370
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
First published online 29 April 2020
doi: 10.1111/bjh.16652
In recent years, several immune regulatory factors have
been discovered to play a role in tumour-mediated immune
escape causing failure of standard therapy. Across different
categories of MDS, alterations in natural killer cells, regula-
tory and cytotoxic T cells, as well as in myeloid-derived sup-
pressor cells, have been reported.9–13 Moreover, therapy can
induce immune reactions and lead to the upregulation of
inhibitory cofactors, such as CTLA-4, PD-L1 and PD-1 in
haematopoietic cells.14 Therefore, the combination of AZA
with checkpoint inhibitors is an emerging new concept to
overcome immune tolerance.
Mechanistic studies of immune escape have linked meta-
bolic alterations and microenvironmental catabolism to
immune tolerance. Indoleamine 2,3 dioxygenase (IDO-1)
catalyses the degradation of tryptophan to kynurenine. Tryp-
tophan is essential for proliferation of cytotoxic T cells and
their immune response.15,16 In addition, kynurenine and
downstream catabolites lead to the upregulation and activa-
tion of regulatory T cells (Tregs), inducing immune suppres-
sion.17,18 In AML, high IDO-1 protein expression, assessed
by immunohistochemistry, is a predictor of poor outcome in
patients who do not undergo HSCT.19 However, to the best
of our knowledge, IDO-1 has not been studied in patients
with MDS treated with HMAs. Therefore, we assessed IDO-1
expression in the bone marrow and its immunoregulatory
capacity in patients with higher-risk MDS treated with




The study population included 95 patients with higher-risk
MDS, sAML or MDS/MPN treated at the Technische Univer-
sit€at M€unchen and Heinrich-Heine Universit€at D€usseldorf
(2004–2013). Informed consent in accordance with the decla-
ration of Helsinki was obtained from all patients. Diagnosis
was made according to the WHO-classification 2016.20 MDS
risk assessment was based on the IPSS-R.21 Karyotypes were
classified according to the new comprehensive cytogenetic
scoring system.22
Treatment consisted of at least three complete cycles of
AZA monotherapy. Patients who had undergone allogeneic
HSCT before AZA treatment were excluded from the study.
Nine patients underwent allogeneic HSCT after AZA treat-
ment.
Definition of response and survival
Response to AZA treatment was scored according to the
modified international working group criteria for MDS.23
Reaching stable disease (SD) with haematological improve-
ment (HI) appears to be associated with improved survival,2
therefore it was also considered a response. The definition of
overall response rate (ORR) included complete remission
(CR), partial remission (PR), marrow CR (mCR) and SD
with HI. Survival was defined from the start of treatment
until death. Patients were censored at the time of last obser-
vation, when still alive.
Immunohistochemistry and immunofluorescence
The following reagents were used: IDO-1 (Cell Signaling,
Beverley, MA, USA) and CD3, CD8, CD11c, CD34, CD47
and CD68 (KP-1) (DAKO GmbH, Hamburg, Germany).
Immunodetection was performed with the REAL detection
kit (DAKO GmbH) and with Cy3-conjugated-goat anti-
mouse and FITC-conjugated-goat anti-rabbit antibodies
(Jackson ImmunoResearch, Cambridge, UK). IDO-1
immunohistochemistry was quantified according to the
immunoreactive score (IRS),24 with staining intensity (score
1–3) multiplied by percent of positive cells (IRS = 0–300).
For further analysis, IRS score was calculated by grading per-
cent of positive cells (0 = 0%; 1 = < 10%; 2 = 10–50%;
3 = 51–80%; 4 = > 80%). Results were divided into low
expression (IRS = 0–3) and high expression (IRS = 6–12);
no samples had a score of IRS = 5/6. Slides were scanned
and analysed with Vectra Polaris (Perkin Elmer, Waltham,
MA, USA).
Cell culture
The human MDS cell lines SKK-1 and MDS-L were cul-
tured in RPMI-1640 with 10% heat-inactivated fetal bovine
serum (Gibco, Thermo fisher scientific, Waltham, MA,
USA). The medium for MDS-L additionally contained
50 µmol/l ß-mercaptoethanol, 2 mmol/l L-glutamine,
10 mmol/l HEPES and 10 ng/ml IL-3 (R&D systems, Min-
neapolis, ME, USA). Human CD8+ T cells were purchased
from Stem Cell Technologies (Cologne, Germany). For
mitogen stimulation, 100 ng/ml anti-CD3 (OK3; Ortho Bio-
tech, Rariton, NJ, USA) and 1 µg/ml CD28 (Pharmingen,
BD Bioscience, San Jose, CA, USA) were used. When indi-
cated, tryptophan (10 µmol/l; Sigma Aldrich, St. Louis, MI,
USA) or IDO-1 inhibitor BMS-986205 (5 to 50 nmol/l; Sel-
leck, Houston, TX, USA) were added. Tryptophan and
kynurenine were quantified by ELISA (ImmuSmol, Pessac,
France).
Statistical analysis
Clinical characteristics were compared with the v2-test for
categorical and Student’s t-test for continuous variables. The
association between clinical and histopathological variables
was investigated using logistic regression. Cox proportional
hazard models and Kaplan–Meier curves were used to assess
the association of variables with OS. The significance level
was set at 005, and analysis was conducted with SPSS version
25 (IBM, Chicago, IL, USA).
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Results
Main patient characteristics
The demographic and clinical characteristics of the 95 patients
are listed in Table I. The median age was 71 years. Of 61
patients with MDS, 28 patients with sAML and six with MDS/
MPN, none belonged to the very low-risk cytogenetic risk
group; 29 patients had a good-risk karyotype; 15 patients had
an intermediate-risk karyotype; 20 patients had a poor-risk
karyotype; and 31 patients had a very poor-risk karyotype.
Patients survived for a median of 102 months (median OS
of MDS patients was 126 months and median OS of AML
patients was 75 months). ORR of patients was 39% (MDS
patients’ ORR was 42% and AML patients’ ORR was 37%); four
patients achieved CR, one patient achieved partial remission
(PR), 11 patients achieved marrow CR (mCR) and 21 achieved
stable disease (SD) with haematological improvement (HI).
Macrophages and myelomonocytic cells of patients with
MDS express IDO-1
We observed cytoplasmic IDO-1 positivity in mature macro-
phages (CD68+) and in a subset of mature to immature cells,
characterised by a round or bean-shaped nucleus with coarse
chromatin (Fig 1A). Double immunofluorescence with IDO-
1 and CD11c (myelomonocytic cells) showed clear colocalisa-
tion of IDO-1 and CD11c. Immunofluorescence with IDO-1,
CD68 and CD34 (marrow blasts) showed that few mature
macrophages were positive for IDO-1 and bone marrow
blasts were negative (not shown). Hence, we could identify
IDO-1 positivity not in CD34+ blasts but in mature macro-
phages, as well as in myelomonocytic cells of the bone mar-
row.
Thirty-five patients (37%) showed moderate to high cyto-
plasmic expression of IDO-1 (IRS 6-12), and 60 patients
(63%) were negative or showed only weak expression of
IDO-1 (IRS 0–3) (Fig 1D).
IDO-1 expression does not correlate with most well-
established clinicopathological parameters, but correlates
with CD8+ T cells
No significant differences in age, gender, diagnosis, number
of marrow blasts, IPSS-R or p53 positivity were observed, as
detailed in Table I. Only the cytogenetic risk classification
showed a significance (P = 0014), with more patients in the
Table I. Patient characteristics in the overall cohort by IDO-1 positivity.
IDO-1+ (n = 35) IDO-1 negative (n = 60) P-value
Age




Male 69 (24) 55 (33) n.s.
Female 31 (11) 45 (27)
MDS/WHO 2016 (%)
MLD 3 (1) 5 (3) n.s.
EB1 3 (1) 12 (7)
EB2 60 (21) 47 (28)
Saml 23 (8) 33 (20)
MDS/MPN 11 (4) 3 (2)
Marrow blasts (%)
0–4 9 (3) 8 (5) n.s.
5–9 6 (2) 12 (7)
10–19 63 (22) 47 (28)
≥20 23 (8) 33 (20)
IPSS-R
Very good 0 (0) 0 (0) 0014
Good 29 (10) 32 (19)
Intermediate 31 (11) 7 (4)
Poor 14 (5) 25 (15)
Very poor 26 (9) 37 (22)
p53 (IHC)
Positive 26 (9) 35 (21) n.s.
Negative 74 (26) 65 (39)
IDO-1, Indoleamine 2,3 dioxygenase; MDS, myelodysplastic syndromes; WHO, World Health Organization; MLD, multilineage dysplasia; EB,
excess blasts; sAML, secondary acute myeloid leukaemia; MPN, myeloproliferative neoplasms; IPSS-R, revised international prognostic scoring
system; IHC, immunohistochemistry; n.s., not significant.
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poor (25% vs. 14%) or very poor (37% vs. 26%) risk group
and fewer patients in the intermediate (7% vs. 31%) risk
group in the IDO-1-negative subgroup.
Because IDO-1 can directly upregulate Tregs (FOXP3+)
and suppresses proliferation of cytotoxic T-lymphocytes
(CD8+) (20, 21), we studied the immunoregulatory function
of IDO-1 in our samples. We quantified T cells (CD3), CD8+
T cells, FOXP3+ T cells, PD1+ T cells, PDL1+ cells, TIM3+
cells and CD47+ leukocytes and performed regression analy-
sis. PDL1 was expressed by bone marrow blasts and
macrophages (Fig S1). Baseline CD8/CD3 ratio was 046 for
MDS patients and 037 for AML patients. Interestingly, we
observed a strong negative correlation between the CD8/CD3
ratio to IDO-1 expression (R2 = 071, P < 00001), whereas
the correlation between IDO-1 and FOXP3 (R2 = 0037,
P = 0060), PD1 (R2 = 00263, P = 01163), PDL1
(R2 = 00175, P = 02012), TIM3 (R2 = 00387, P = 0056)
or CD47 (R2 = 423 9 103, P = 095) expression did not
reach statistical significance (Fig 2), with a trend towards sig-
nificance for FOXP3 and TIM3.
Fig 1. IDO-1 expression in bone marrow samples. IHC analysis was performed with IDO-1, and a moderate to high cytoplasmic IDO-1 expres-
sion can be observed in a subset of bone marrow samples (A). Double immunofluorescence analysis (B) with IDO-1 (green, FITC-conjugated sec-
ondary antibody (1)) and with CD11c (red, Cy3-conjugated secondary antibody (2)) shows co-expression of IDO-1 and CD11c (yellow, overlay
of red and green (4)). IHC analysis of bone marrow samples showed IDO-1 negativity (C1), low expression of IDO-1 (C2) and strong expression
of IDO-1 (C3). IDO-1 expression was semi-quantified by IRS; 63% of bone marrow samples were negative or showed weak expression of IDO-1
and 37% of bone marrow samples showed moderate to high expression of IDO-1 (D).
C. M€uller-Thomas et al.
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IDO-1 expression predicts response to AZA treatment
While it has been shown that AZA treatment can induce
immune reactions, IDO-1 can inhibit immune reactions.
As IDO-1 expression was correlated negatively with the
CD8/CD3 ratio, suggesting an immunosuppressive role
of IDO-1 in our samples, we next analysed whether
IDO-1 expression has any impact on response to AZA
treatment.
In the IDO-1– group, the ORR was 52%, with an AZA
treatment failure rate of 48%. In contrast, in the IDO-1+
group, the majority of patients showed treatment failure
(83%), with an ORR of 17% (P < 0001; Table II and Fig 3).
Other factors (age, MDS type, p53- status) did not reach sta-
tistical significance (Table S1).
IDO-1 expression is a predictive factor of survival in
patients treated with AZA
Moreover, IDO-1 expression did not only predict response
to therapy but was also associated with OS. Univariate analy-
sis showed significantly-improved survival in IDO-1– patients
(214 months) compared to IDO-1+ patients (108 months)
(HR 0615; P = 0034) (Fig 4). No other markers signifi-
cantly influenced OS, including the IPSS-R (HR 149;
P = 0127), sex (HR 1008; P = 0971), age ≤ 60 versus > 60
(HR 2403; P = 006), sAML versus MDS (HR 1153;
P = 0550), cytogenetic risk group (HR 107; P = 0426) and
p53 status (HR 0983; P = 0884) (Fig 3).
To examine, if IDO-1 expression itself adds prognostic
information to the IPSS-R multivariable analysis for survival
was conducted. Multivariable analysis for survival was con-
ducted to examine, if IDO-1 expression itself adds prognostic
information to the IPSS-R (Table III).
IDO-1 expression correlates with CD8+ T cell response
failure after AZA treatment
We identified 15 patients (5 IDO-1+; 10 IDO-1–) with fol-
low-up bone marrow biopsies under AZA treatment which
allowed us to obtain their status before and after/under AZA
treatment. Remarkably, we observed a high and long-lasting
increase in CD8+ T cells in all IDO-1– patients; however, in
IDO-1+ patients, the number of CD8+ T cells did not
Fig 2. Correlation of IDO-1 expression with CD8/CD3 ratio in bone marrow samples. IHC analysis was performed with IDO-1 (A), CD3 (B)
and CD8 (C). Correlation studies showed that IDO-1 expression inversely correlated significantly with the ratio of infiltrating CD8/CD3 positive
T cells (D) with R2 = 071 (Pearson correlation; total of 95 patients).
Table II. Response to azacytidine according to IDO-1 expression.
IDO-1 negative (n = 35) IDO-1+ (n = 60)
CR 330% (2) 290% (1)
PR 330% (2) 0% (0)
BM-CR 1670% (10) 0% (0)
SD + HI 25% (15) 1420% (5)
Failure 4830% (29) 8290% (29)
ORR 5170% (31) 1710% (6)
CR, complete remission; PR, partial remission; BM-CR, bone mar-
row complete remission; SD + HI, stable disease with haematological
improvement; ORR, overall response rate.
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Fig 3. Correlation of IDO-1 expression and response to treatment as well as overall survival depending on IDO-1 expression. Correlation of
IDO-1 expression and response to therapy was analysed by v2 test (A). 83% of the IDO-1+ patients failed to therapy, with 17% of ORR; in con-
trast, the overall response rate was 52% in the IDO-1 negative group (P < 00001). Kaplan–Meier curves for overall survival (B), with IDO-1+
and IDO-1 negative patients showing significantly shorter OS for IDO-1+ patients.
Fig 4. Increase of infiltrating CD8+ T cells in patients treated with AZA. Representative IHC analysis (A) of an IDO-1+ (patient 1) and of an
IDO-1 negative patient (patient 2); displayed is the IDO-1 expression and the CD8-IHC before and after AZA treatment. Under AZA treatment a
clear increase in the number of CD8+ T cells in IDO-1 negative patients with nearly no increase in IDO-1+ patients can be observed (B; Y-axis
displays median gain of CD8+ T cells). This difference was statistically significant at all time points (C).
C. M€uller-Thomas et al.
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increase over time (Fig 4A,B). The difference in increase of
CD8+ T cells was statistically significant (P < 0001)
(Fig 4C). We could also observe a decrease of Tregs, which
was higher in IDO-1– MDS (P = 0061).
IDO-1 in MDS cell lines leads to catabolism of
tryptophan and depletion of CD8+ T-lymphocytes
It is well documented that cytotoxic (CD8+) T cells stop pro-
liferating under tryptophan starvation. Therefore, we wanted
to test if tryptophan in the cell culture medium can be meta-
bolised by IDO-1+ MDS cell lines, and if proliferation of
CD8+ T cells is indeed dependent on tryptophan under these
conditions.
We cultured two MDS cell lines, SKK1 and MDS-L, with
high expression of IDO-1 (Fig 5A) for 72 h. ELISA of the
conditioned medium showed a nearly complete depletion of
tryptophan to < 05 µmol/l (02 µmol/l  02), with subse-
quent increase in kynurenine to 205  1 µmol/l in both cell
lines, which could be prevented by IDO-1 inhibition
(Fig 5B).
IDO-1 inhibition had no direct effect on proliferation of
the MDS cell lines, nor on the proliferation of CD8+ T cells
(data not shown). We next investigated if tryptophan deple-
tion in conditioned medium could reduce T cell prolifera-
tion. Activated CD8+ T cells stimulated with anti-CD3
(100 ng/ml) and CD28 (1 µg/ml) were cultured in condi-
tioned medium and normal growth medium for 48 h, and
proliferation was measured by MTT-assay. T cells grown in
conditioned medium showed a significant reduction of rela-
tive proliferation to 20–25%, which could be nearly rescued
by adding tryptophan to the medium (Fig 5C).
Discussion
In recent years, IDO-1 has emerged as a key target in cancer
immunotherapy because it can induce tumour immune
escape in various cancers.25 Thus far, evidence supporting a
role for this pathway in MDS is lacking, and the effect of
IDO-1 expression under AZA treatment, a treatment that
induces certain immune reactions, has not yet been studied.
In this study, we first demonstrated that IDO-1 is
expressed in the bone marrow samples of patients with
higher-risk MDS. We performed a comprehensive analysis of
patients (n = 95) treated homogeneously with AZA, while
most previous studies have examined combined AZA or dec-
itabine treatments.26–28 Our cohort patients with higher-risk
MDS is in line with the approval of AZA.29,30 We observed
cytoplasmic expression of IDO-1 in macrophages and
myelomonocytic cells; however, we did not observe IDO-1
expression in bone marrow blasts. In a recent study of 29
AML patients,19 IDO-1 expression in leukemic blasts was
found to be predictive of early mortality, though double
immunofluorescence staining was not performed to truly
clarify which cells were expressing IDO-1. Our observations
are in line with numerous publications on solid tumours,
lymphomas and melanomas,31–33 in which IDO-1 expression
has been observed in the tumour cells themselves, as well as
in by-standing antigen-presenting cells. Recently, it was also
demonstrated that the levels of tryptophan metabolites are
elevated in the sera of patients with MDS, and that higher
tryptophan metabolite levels correlated with degree of
cytopenia.34
The main focus of our study was the immunomodulatory
role of IDO-1 in MDS; therefore, we quantified infiltrating
macrophages, T cells and specific T cell subsets. We observed
only a small number of Tregs, and IDO-1 expression did not
correlate with the number of Tregs. This is in contrast to
previous studies showing that IDO-1 can activate Tregs and
block their conversion to Th17 cells.35 However, Tregs are
suppressed by multiple cytokines (such as TGF-b, IL-10 and
IL-35),36 and, particularly, overactivation of the TGF-b path-
way (which could eventually prevent IDO-1-induced Treg
activation and proliferation) is well documented in MDS.37
The bone marrow samples displayed a moderate to high
number of infiltrating macrophages. Only a few macrophages
were IDO-1+, and IDO-1 expression did not correlate with
the number of infiltrating macrophages. This is not surpris-
ing, as it is well documented that in some (but not all)
tumours, tumour cells can lead to the upregulation of IDO-1
in their microenvironment, yet an induction of macrophage
proliferation has not been observed thus far. An important
and common mechanism of IDO-1 in promoting tumour
immune escape is the catabolism of tryptophan, which leads
to the cell cycle arrest and apoptosis of cytotoxic T cells.16
Indeed, IDO-1 expression correlated inversely with the CD8/
CD3 ratio in the bone marrow in our cohort. This is an
exciting observation, which suggests that IDO-1 might be a
key factor in the induction of an immunosuppressive bone
marrow environment in MDS patients.
IDO-1 expression could not only predict the response to
therapy, it was also the only prognostic factor for survival,
and had an independent prognostic impact in multivariate
analysis. In contrast, univariate analysis showed that IPSS-R,
gender and p53 status could not predict response to AZA or
survival. This is consistent with several publications in which
TP53 mutations conferred a poor prognosis but were not
predictive of the response to therapy,6,38,39 while IPSS-R,
Table III. Multivariate analysis of prognostic scores and IDO-1
expression.
HR P
IDO-1 expression 0626 0042
Medullary blasts according to IPSS-R 1141 0371
Cytopenia according to IPSS-R 0607 0194
Cytopenetics according to IPSS-R 1138 0177
IDO-1, Indoleamine 2,3 dioxygenase; IPSS-R, revised international
prognostic scoring system.
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gender and age did not qualify as predictors of response to
therapy or survival. HMAs can potentiate antitumour immu-
nity by inducing the expression of critical molecules involved
in cognate recognition by cytotoxic T cells, such as MHC I
and ICAM-1. Consequently, the T cell-mediated elimination
of tumour cells is enhanced due to T cell recruitment and
proliferation after reactivation.40,41 IDO-1 expression corre-
lated inversely with the CD8/CD3 ratio in our bone marrow
samples; therefore, it might well be that IDO-1 counteracts
the immune cell activation of AZA and thereby promotes
resistance to therapy.
The level of CD8+ T cells clearly increased after/under
AZA treatment and remained constantly high. As stated
above, HMA can stimulate the antitumour immune response,
including activation and upregulation of antigen-specific
cytotoxic T-lymphocytes.42,43 Excitingly, in all our IDO-1–
patients, we observed an increase in CD8+ T-lymphocytes; in
contrast, all IDO-1+ patients showed constant low numbers
of CD8+ T-lymphocytes, with no or only a slight transient
increase (Fig 5). This effect was seen early during AZA treat-
ment and drove our decision to include patients being trea-
ted with < 6 cycles AZA as well.
Functionally, IDO-1+ cell lines were able to catabolise
tryptophan with subsequent increase of kynurenine, which
led to depletion of T cells (Fig 5). Interestingly, the prolifera-
tion arrest could be rescued by addition of tryptophan. Pre-
viously,44 it had been shown that human bone marrow
stromal cells are capable of inhibiting allogeneic T cell
responses; however, an induction of an immunosuppressive
environment by MDS cells has not been demonstrated so far.
Our findings and functional experiments strengthen our
hypothesis that IDO-1+ MDS can evade the antitumour
immune response, thereby leading to AZA treatment failure.
This has clear implications for the development of new ther-
apeutic strategies in the treatment of MDS. There are multi-
ple IDO inhibitors in clinical trials.45 Although a phase II
trial of IDO-1 inhibitor46 in 15 MDS patients has been dis-
appointing, combinations of IDO-1 inhibitors with other
chemotherapies or checkpoint inhibitors have resulted in
promising ORRs in solid tumours47–49 and warrant further
investigation in MDS on the basis of our data.
In conclusion, IDO-1 is expressed in macrophages and
myelomonocytic cells of the bone marrow in patients with
MDS, and is a predictor of both treatment failure and
shorter OS under AZA treatment. Interestingly, IDO-1
expression was correlated inversely with the ratio of infiltrat-
ing CD8+ T cells, and in IDO-1+ patients, an increase in
CD8+ T cells under AZA treatment was not observed. There-
fore, IDO-1 positivity in the bone marrow might be useful
for identifying patients with a low probability of achieving
clinical benefit from HMA. In addition, our data further dis-
tinguish IDO-1 as an emerging promising target, especially
for combination therapies with HMA in patients with
higher-risk MDS.
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Fig 5. Tryptophan metabolism by MDS cell lines and inhibition T cell proliferation Western blot analysis of SKK (A) and MDS-L (B) cell line dis-
play constant high expression of IDO-1 under BMS-986205 treatment in various concentrations (0–50 nmol/l). Tryptophan is catabolised in con-
ditioned medium of SKK and MDS-L; simultaneously, kynurenine levels are increasing as measured by ELISA (C). MTTassays (D) show a clear
reduction of T cell proliferation in conditioned medium (SKK, MDS-L), which can be rescued by addition of tryptophan (SKK-T, MDS-L-T).
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Fig S1. PDL1 expression in MDS bone marrow.
Table S1. Univariate analysis of overall response rate
(ORR)
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